Neurodegenerative disease management最新文献_第5页

Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon β-1a users. 患者报告的结果是肌内干扰素β-1a使用者疾病失能的最强预测因子。

IF 2.6

Neurodegenerative disease management Pub Date : 2023-06-01 DOI: 10.2217/nmt-2022-0008

Caila B Vaughn, Katelyn S Kavak, Dejan Jakimovski, Natasha Qutab, Robin Avila, Megan Vignos, Bianca Weinstock-Guttman

{"title":"Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon β-1a users.","authors":"Caila B Vaughn, Katelyn S Kavak, Dejan Jakimovski, Natasha Qutab, Robin Avila, Megan Vignos, Bianca Weinstock-Guttman","doi":"10.2217/nmt-2022-0008","DOIUrl":"https://doi.org/10.2217/nmt-2022-0008","url":null,"abstract":"Introduction: Patient-reported outcomes (PROs) are valuable measures for routine clinical care of people with multiple sclerosis (pwMS). Materials: 646 pwMS treated with interferon-β-1a (IFN-β-1a) were retrospectively included from the New York State Multiple Sclerosis Consortium. Clinical and PRO data at enrollment and 3 year follow-up were collected. PwMS with stable disease and disability worsening were matched (1:1) based on age, Expanded Disability Status Scale (EDSS) scores and disease duration. Disability worsening was determined based on trial criteria. Results: PwMS with future EDSS worsening had higher baseline and follow-up timed-25-foot walk (6.6 vs 5.5 s; 9.1 vs 5.5 s; p < 0.001) when compared with stable pwMS. Worsening pwMS reported higher baseline difficulties in getting up (odds ratio [OR] = 2.4; p = 0.009), climbing stairs (OR = 1.6; p = 0.024) and standing (OR = 2.2; p < 0.001). Worsening pwMS reported greater lower limb limitations (OR = 2.3; p = 0.004) and fatigue (OR = 1.8; p = 0.002). Conclusion: Higher fatigue and lower limb functional limitations are significant predictors of future disability worsening in pwMS.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9672864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

5-HT_1A agonists for levodopa-induced dyskinesia in Parkinson's disease. 5-HT1A激动剂治疗帕金森病左旋多巴诱导的运动障碍。

IF 2.6

Neurodegenerative disease management Pub Date : 2023-04-01 DOI: 10.2217/nmt-2022-0039

Jawad Al-Kassmy, Christine Sun, Philippe Huot

引用次数: 0

Parkinson's disease research in Morocco: a review. 摩洛哥帕金森病研究综述

IF 2.6

Neurodegenerative disease management Pub Date : 2023-04-01 DOI: 10.2217/nmt-2022-0021

Mohamed Daghi, Abdelhakim Lakhdar, Hicham El Otmani

引用次数: 0

Interview with Nobutaka Hattori: a life researching Parkinson's disease pathogenesis. 专访服部信孝:研究帕金森病发病机制的一生。

IF 2.6

Neurodegenerative disease management Pub Date : 2023-04-01 DOI: 10.2217/nmt-2023-0010

Nobutaka Hattori

引用次数: 0

Early approaches of YKL-40 as a biomarker and therapeutic target for Parkinson's disease. YKL-40作为帕金森病生物标志物和治疗靶点的早期研究

IF 2.6

Neurodegenerative disease management Pub Date : 2023-04-01 DOI: 10.2217/nmt-2022-0010

Mai M Anwar, Mohamed H Fathi

引用次数: 4

The effect of auditory cues on gait variability in people with Parkinson's disease and older adults: a systematic review. 听觉提示对帕金森病患者和老年人步态变异性的影响:一项系统综述。

IF 2.6

Neurodegenerative disease management Pub Date : 2023-04-01 DOI: 10.2217/nmt-2021-0050

Elinor C Harrison, Gammon M Earhart

引用次数: 2

Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes. 阿波啡舌下膜和左旋多巴对OFF发作患者的运动反应。

IF 2.6

Neurodegenerative disease management Pub Date : 2023-04-01 DOI: 10.2217/nmt-2022-0038

Stuart H Isaacson, Alyssa Bowling, Ian Zhang, Eric Pappert, Fabrizio Stocchi

引用次数: 1

Updates and advances in multiple sclerosis neurotherapeutics. 多发性硬化症神经疗法的最新进展。

IF 2.6

Neurodegenerative disease management Pub Date : 2023-02-01 Epub Date: 2022-10-31 DOI: 10.2217/nmt-2021-0058

Moein Amin, Carrie M Hersh

引用次数: 0

Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary. 专家意见对COVID-19疫苗和克拉德里滨片在MS:一个简单的语言总结。

IF 2.6

Neurodegenerative disease management Pub Date : 2023-02-01 DOI: 10.2217/nmt-2022-0027

Peter Rieckmann, Diego Centonze, Gavin Giovannoni, Le H Hua, Celia Oreja-Guevara, Daniel Selchen, Per Soelberg Sørensen, Patrick Vermersch, Heinz Wiendl, Hashem Salloukh, Bassem Yamout

{"title":"Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary.","authors":"Peter Rieckmann, Diego Centonze, Gavin Giovannoni, Le H Hua, Celia Oreja-Guevara, Daniel Selchen, Per Soelberg Sørensen, Patrick Vermersch, Heinz Wiendl, Hashem Salloukh, Bassem Yamout","doi":"10.2217/nmt-2022-0027","DOIUrl":"https://doi.org/10.2217/nmt-2022-0027","url":null,"abstract":"What is this summary about?: People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsing-remitting or active secondary progressive disease) taking cladribine tablets.What were the results?: The committee identified 13 recommendations, which were all agreed upon by at least three-quarters (75%) of the 38 voting MS experts. Generally, they recommended that people with MS taking cladribine tablets should be vaccinated for COVID-19 as soon as possible, because the vaccine is thought to be both safe and effective, and vaccine responses were not likely to be affected by cladribine tablets.What do the results mean?: Overall, people with MS taking cladribine tablets should receive the COVID-19 vaccine to protect themselves, unless advised differently by their healthcare provider.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10590342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets. 用克拉德里滨片治疗多发性硬化症患者，对流感和水痘疫苗的影响的简单语言总结。

IF 2.6

Neurodegenerative disease management Pub Date : 2023-02-01 DOI: 10.2217/nmt-2022-0026

Klaus Schmierer, Heinz Wiendl, Celia Oreja-Guevara, Diego Centonze, Anita Chudecka, Sanjeev Roy, Ursula Boschert

{"title":"A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets.","authors":"Klaus Schmierer, Heinz Wiendl, Celia Oreja-Guevara, Diego Centonze, Anita Chudecka, Sanjeev Roy, Ursula Boschert","doi":"10.2217/nmt-2022-0026","DOIUrl":"https://doi.org/10.2217/nmt-2022-0026","url":null,"abstract":"What is this summary about?: This is a summary of an article originally published in the Multiple Sclerosis Journal. Cladribine tablets (MAVENCLAD®) are an oral (taken by mouth) medication, approved for the treatment of people with relapsing forms of multiple sclerosis (MS, with episodes of new or worsening symptoms). They are administered for a maximum of 10 days per year, over a period of 2 years. Cladribine tablets work by temporarily reducing the number of lymphocytes, which are immune cells that help to fight off infections. Because of this, people with MS (also called PwMS) may have concerns about the effect of cladribine tablets on vaccines, as these work via immune cells to build protection against infection.What happened in the magnify-ms study?: A study called MAGNIFY-MS investigated how long it takes for cladribine tablets to begin to work in people with a type of MS called highly active relapsing MS. During the study, some participants received their usual vaccinations against flu (influenza) and against the chickenpox virus (also called varicella zoster virus) as part of their routine medical care. The MAGNIFY-MS study gave the researchers an opportunity to look at how cladribine tablets affect the way the flu and chickenpox virus vaccines work in the body.What were the results?: Cladribine tablets do not affect how well the body responds to flu and chickenpox vaccines.What do the results mean?: PwMS taking cladribine tablets who are vaccinated against chickenpox, flu or both can be protected against these diseases.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9361631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0